Showing results (1891-1900 of 2,232) with videos related to

Sort By:
Pageof 224
Zoological Research|May 17, 2021
LIN28A inhibits DUSP family phosphatases and activates MAPK signaling pathway to maintain pluripotency in porcine induced pluripotent stem cellsXiao-Long Wu, Zhen-Shuo Zhu, Xia Xiao, et al.
BMC Rheumatology|May 5, 2026
Progression of non-radiographic to radiographic axial spondyloarthritis: a risk model based on a chinese cohort studyRui-Ying Deng, Xiao-Jia Xu, Jian-Hua Peng, et al.
Biomarker Research|March 6, 2023
Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumorsDingwei Ye, Jayesh Desai, Jingwen Shi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 21, 2024
Radiomics-Based Support Vector Machine Distinguishes Molecular Events Driving the Progression of Lung AdenocarcinomaHong-Ji Li, Zhen-Bin Qiu, Meng-Min Wang, et al.
Journal of Translational Medicine|July 12, 2013
Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapiesXu-chao Zhang, Jingchuan Zhang, Ming Li, et al.
European Journal of Cancer (Oxford, England : 1990)|February 11, 2019
A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002)Zhen Wang, Cheng Huang, Jin-Ji Yang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2017
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858RE-E Ke, Qing Zhou, Qiu-Yi Zhang, et al.
Therapeutic Advances in Medical Oncology|February 9, 2024
Plasma ddPCR for the detection of MET amplification in advanced NSCLC patients: a comparative real-world studyJun-Wei Su, Cheng-Di Weng, Xiao-Cheng Lin, et al.
Cancer|June 7, 2023
Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancerQing Zhou, Jun Zhao, Jianhua Chang, et al.
The Lancet. Oncology|June 9, 2015
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6James C-H Yang, Lecia V Sequist, Sarayut Lucien Geater, et al.
Pageof 224